PBYI News and Press, Puma Biotechnology Inc From 08/13/21

Puma Biotechnology recently reported their Q2 earnings that revealed a beat on EPS and revenue. Unfortunately, the market continues to crush PBYI, which is down ~50% from February. The company reported respectable sequential growth and improvements in commercial trends. It appears the...

The following slide deck was published by Puma Biotechnology, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Puma Biotechnology, Inc. 2021 Q2 - Results - Earnings Call Presentation

Puma Biotechnology, Inc. (PBYI) Q2 2021 Earnings Conference Call August 05, 2021, 16:30 ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Founder, Chairman, President, CEO & Secretary Jeffrey Ludwig - Chief Commercial Officer Maximo Nougues - CFO & Princi...

Puma Biotechnology (NASDAQ:PBYI): Q2 Non-GAAP EPS of $0.32 beats by $0.46; GAAP EPS of -$0.13 beats by $0.14. Revenue of $53.4M (-24.4% Y/Y) beats by $1.1M. Press Release For further details see: Puma Biotechnology EPS beats by $0.46, beats on revenue

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2021. Unless otherwise stated, all comparisons are for the second quarter of 2021 compared to the second quarter of 2020. Product revenue, net cons...

Cowen has initiated shares of Celcuity (CELC +6.2%) with an overweight rating but no price target. The company is developing a companion diagnostic, CELsignia, for breast cancer. CELsignia uses live tumor cells derived from a patient biopsy and measures real-time activity changes in response ...

Biopharmaceutical company Puma Biotechnology (PBYI) has entered into a $125M note purchase transaction with healthcare-focused asset management company Athyrium Capital.Puma received $100M in gross proceeds from the first tranche of notes it issued as part of the agreement. The funds, along w...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has entered into a note purchase agreement with a fund of Athyrium Capital Management, LP, a specialized asset management company focused on opportunities in the global healthcare sector, for the iss...

Knight Therapeutics (KHTRF) announces that Health Canada has approved Nerlynx (neratinib) in combination with capecitabine for the treatment of adult patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens.The approval ...

MONTREAL, July 06, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine for the treatment of...